To screen the targets and related signaling pathways of Astragali Radix-Cordyceps in the treatment of IgA nephropathy (IgAN) by network pharmacology,to clarify its mechanism of action,and to verify it experimentally.TCMSP and BATMAN-TCM databases combined with literature mining were used to obtain the active components and targets of Astragali Radix-Cordyceps;the disease targets of chronic IgAN were obtained through GeneCards and OMIM databases;Venny 2.1 was used to draw a Venn diagram of common targets;STRING was used to build a common target interaction network (PPI);Cytoscape 3.7.1 software was used to build an interaction network of Astragali Radix-Cordyceps pills-target;through R language software GO analysis of common targets and KEGG analysis of chronic IgA nephropathy targets were performed to screen out potential pathways and their mechanisms of action were analyzed.Molecular docking technology was used to verify the binding efficacy of the active components of Astragali Radix-Cordyceps and key targets.IgA nephropathy model rats (model group and Astragali Radix-Cordyceps dose group with high,medium and low doses) were taken for 21 days,respectively,and the kidney tissue was collected to detect the expression of VEGFA protein in the kidney tissue of the rats in each group by Western blot.Five bioactive components were screened out from Astragali Radix-Cordyceps,which acted on 37 common targets of IgAN.The core targets were VEGFA,HIF1A,NOS3,and CASP3,which mainly involved cysteine-type steroid binding and apoptosis,endopeptidase activity,estrogen receptor binding,cholesterol binding and other biological processes are mainly enriched in lipid and atherosclerosis signaling pathway,AGE-RAGE signaling pathway,fluid shear stress and atherosclerosis pathway,PI3K-Akt signaling pathway and other signaling pathways.The molecules showed good binding potency between the main components and key targets.Compared with model group,the expression of VEGFA in the high and low dose groups of Astragali Radix-Cordyceps decreased (P<0.05),and there was no significant difference between the high-dose group and the middle-dose group (P> 0.05).Astragali Radix-Cordyceps may act on key targets such as VEGFA,HIF1A,NOS3,and CASP3,and achieve therapeutic effects on IgA nephropathy through fibrosis and other signaling pathways.